Displaying 1 - 6 of 6 tests
Kappa
Antibody to the kappa light chain of immunoglobulin is reportedly useful in the identification of leukemias, plasmacytomas and certain non-Hodgkin lymphomas. Demonstration of monotypism in lymphoid infiltrates is a surrogate for clonality, and therefore malignancy.
Immunohistochemistry (IHC)
Kappa
Each test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma
In Situ Hybridization (ISH)
Ki67
Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor
Immunohistochemistry (IHC)
KIT (c-KIT) Mutation Analysis
Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. For solid tumors, tumor enrichment is performed before extraction. In hematological disease, testing may be performed on plasma to increase sensitivity.
Molecular
KRAS Exon 4 Mutation Analysis
Bi-directional sequencing of exon 4 of the KRAS gene corresponding to amino acids R97 through Q150. Codon 117 and 146 mutations are detected. For solid tumors, tumor enrichment is performed before extraction. This test may be ordered separately or by reflex after standard KRAS Mutation Analysis.
Molecular
KRAS Mutation Analysis
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. For solid tumors, tumor enrichment is performed before extraction. Testing is available separately or in combination with BRAF, HRAS and
Molecular